Takeda Operating Metrics

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

Takeda key operating metrics including Phase III Trials Products (Oncology), environmental, and social and governance score (ESG).

Phase III Trials Products (Oncology)

Jul, 2023

Phase III Trials Products (PDT)

Jul, 2023

Filed Trials Products (Gastro-Enterology)

25.0%

Jul, 2023

Operating Metrics

Metrics	May, 2020	Jul, 2021	Oct, 2021	Feb, 2021	May, 2021	Jul, 2022	Oct, 2022	Feb, 2022	May, 2022	Jul, 2023
Phase III Trials Products (Oncology)	6	6	6	6	8	8	8	5	6	6
Phase III Trials Products (PDT)	3	4	4	3	7	6	5	4	5	5
Filed Trials Products (Gastro-Enterology)	5	7	7	7	6		2	3	4	3
Phase III Trials Products (Gastro-Enterology)	4	4	4	4	7	7	7	7	9	9
Phase I/II Trials Products (Gastro-Enterology)	1	1	1	1	10	9	10	9	8	7
Filed Trials Products (Rare Genetic & Hematology)	2	2	2	2	3	3	2	3	5	5
Phase III Trials Products (Rare Genetic & Hematology)	4	4	4	4	9	10	10	9	6	6
Phase I/II Trials Products (Rare Genetic & Hematology)	1	1	1	1	7	6	6	6	5	5
Filed Trials Products (Oncology)	4	4	4	4	5
Phase I/II Trials Products (PDT)			1	1	2	2	2	2	1	1
Filed Trials Products (PDT)				1	1	2	3	4	7	5
Phase I/II Trials Products (Vaccines)					1	1	1	1	1	1
Phase III Trials Products (Vaccines)					1	1	2	2	2	2
Filed Trials Products (Vaccines)					3	1	1	2	2
Phase I/II Trials Products (Oncology)					12	12	12	12	12	13
Phase III Trials Products (Neuroscience)					2
Phase I/II Trials Products (Neuroscience)					8	7	8	9	10	10

60-79 out of 100

Community

Employees

Environment

Governance

Premium Content only available in Craft’s Intelligence Portal

Source:CSRHub